Literature DB >> 8113548

Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina.

J C Kaski1, G Rosano, S Gavrielides, L Chen.   

Abstract

OBJECTIVES: This study was conducted to test the hypothesis that angiotensin-converting enzyme inhibition may lessen myocardial ischemia in patients with microvascular angina.
BACKGROUND: Patients with syndrome X (angina pectoris, positive findings on exercise testing and normal coronary arteriogram) have a reduced coronary vasodilator reserve ("microvascular angina") and may show an increased sympathetic drive. Angiotensin-converting enzyme inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease.
METHODS: Ten patients (seven women and three men, mean age [+/- SD] 53 +/- 6 years) with syndrome X and a reduced coronary flow reserve underwent a randomized, single-blind, crossover, placebo-controlled study of the effects of the angiotensin-converting enzyme inhibitor enalapril on angina and exercise-induced ST segment depression. Assessment was by symptom-limited treadmill exercise testing after 2 weeks of treatment with 10 mg/day of enalapril and after 2 weeks of placebo administration.
RESULTS: All patients had positive findings on exercise testing (> or = 1 mm ST segment depression and angina) while taking placebo, whereas six patients had a positive test result (four with angina) during enalapril therapy. Total exercise duration and time to 1 mm of ST segment depression were prolonged by enalapril over those obtained with placebo (mean 779 +/- 141 vs. 690 +/- 148 s, p = 0.006 and 690 +/- 204 vs. 485 +/- 241 s, p = 0.007, respectively). The magnitude of ST segment depression was also less with enalapril than with placebo (mean 1.1 +/- 0.4 vs. 1.5 +/- 0.2 mm, p = 0.004). Heart rate and blood pressure at peak exercise and at 1 mm of ST depression were not significantly different during placebo and enalapril treatment.
CONCLUSIONS: Angiotensin-converting enzyme inhibition lessens exercise-induced ischemia in patients with syndrome X and microvascular angina, probably by a direct modulation of coronary microvascular tone, which results in an increased myocardial oxygen supply.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113548     DOI: 10.1016/0735-1097(94)90750-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  The effects of the angiotensin II receptor (type I) antagonist irbesartan in patients with cardiac syndrome X.

Authors:  Stuart J Russell; Eugenie M Di Stefano; Mahmud T Naffati; Oliver Brown; Stephen Saltissi
Journal:  Heart       Date:  2007-02       Impact factor: 5.994

Review 2.  Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms.

Authors:  Richard O Cannon
Journal:  J Am Coll Cardiol       Date:  2009-09-01       Impact factor: 24.094

3.  Angina in Women without Obstructive Coronary Artery Disease.

Authors:  Kamakki Banks; Monica Lo; Amit Khera
Journal:  Curr Cardiol Rev       Date:  2010-02

Review 4.  Coronary microvascular dysfunction, microvascular angina, and treatment strategies.

Authors:  Mark A Marinescu; Adrián I Löffler; Michelle Ouellette; Lavone Smith; Christopher M Kramer; Jamieson M Bourque
Journal:  JACC Cardiovasc Imaging       Date:  2015-02

5.  In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE).

Authors:  Daniel F Pauly; B Delia Johnson; R David Anderson; Eileen M Handberg; Karen M Smith; Rhonda M Cooper-DeHoff; George Sopko; Barry M Sharaf; Sheryl F Kelsey; C Noel Bairey Merz; Carl J Pepine
Journal:  Am Heart J       Date:  2011-09-06       Impact factor: 4.749

Review 6.  Microvascular angina: assessment of coronary blood flow, flow reserve, and metabolism.

Authors:  Mark R Vesely; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2011-04       Impact factor: 2.931

Review 7.  'Primary' Microvascular Angina: Clinical Characteristics, Pathogenesis and Management.

Authors:  Gaetano Antonio Lanza; Antonio De Vita; Juan-Carlos Kaski
Journal:  Interv Cardiol       Date:  2018-09

Review 8.  Microvascular coronary dysfunction and ischemic heart disease: where are we in 2014?

Authors:  John W Petersen; Carl J Pepine
Journal:  Trends Cardiovasc Med       Date:  2014-11-07       Impact factor: 6.677

Review 9.  Cardiac Syndrome X: update 2014.

Authors:  Shilpa Agrawal; Puja K Mehta; C Noel Bairey Merz
Journal:  Cardiol Clin       Date:  2014-06-02       Impact factor: 2.213

Review 10.  Syndrome X--angina and normal coronary angiography.

Authors:  A Chauhan
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.